Jeuveau® is an injectable manufactured by Evolus and approved by the FDA. This injectable treatment that was originally designed to smooth away moderate to severe frown lines between the eyebrows to create a more youthful appearance in men and women.
Jeuveau is similar to Botox but offers a cheaper solution that can have longer-lasting results. Just like Botox, Jeaveau does require periodic treatment, although since it is less expensive and can last longer than Botox, it may offer a more suitable treatment option for patients who want to get rid of those pesky frown lines (called glabellar lines).
How Jeaveau is Used
When injected into the face, Jeuveau temporarily prevents your nerves from telling your facial muscles to flex. Our Medical Spa uses Jeaveau injections for the following purposes:
- Worry Lines – Horizontal forehead lines that can appear with aging.
- Glabellar Lines – These are the vertical frown lines between the eyebrows.
- Crow’s Feet – These smile lines directly beside your eyes.
- Naris – These are “bunny lines” when you scrunch your nose.
- Nose Flare – When nostrils are more pronounced when smiling, inhaling, laughing or when static and at rest.
- Gummy Smile – A gummy smile is when the upper gums are too apparent when a person smiles.
- Fine Lip Lines – When you have fine vertical lines, often stretching from one side of the mouth to the other.
- “Golf ball” Chin – As the chin is pulled up with the mentalis muscles, a dimpling effect is achieved. This is also known as peau d’orange or golf ball chin.
- Platysmal Bands – This is caused by aging and occurs when two edges of the neck muscles run up the front left and right sides of your neck mid-line.
- Masseters – The masseter muscles can become larger and overdeveloped, which alters the shape of the lower face and creates a square jawline.
- Axillary Hyperhidrosis – Excessive sweating to underarms.
Expected Jeuveau Results
In clinical trials, Jeuveau was shown to temporarily improve the appearance of moderate to severe frown lines. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician and patient-rated improvement in frown lines at Day 30. In a study conducted in Europe and Canada, 54% of patients had visible results as early as 2 days after treatment.* And at 5 months after treatment, 38% of patients had visible results with Jeuveau® **
* 54% of patients had a >1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint). In US studies, 46% and 56% had a >1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.
** 38% of patients had a >1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint). In US studies, almost 5% of patients had a >2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint). Results based on a 1-grade improvement may not be considered clinically meaningful.
